Details

Autor(en) / Beteiligte

• Holz, Frank G
• Tadayoni, Ramin
• Beatty, Stephen
• Berger, Alan
• Cereda, Matteo Giuseppe
• Hykin, Philip
• Staurenghi, Giovanni
• Wittrup-Jensen, Kim
• Altemark, Andreas
• Nilsson, Jonas
• Kim, Kun
• Sivaprasad, Sobha

Titel

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study

Ist Teil von

• British journal of ophthalmology, 2016-12, Vol.100 (12), p.1623-1628

Ort / Verlag

England: BMJ Publishing Group LTD

Erscheinungsjahr

2016

Quelle

BMJ Journals Archiv - DFG Nationallizenzen

Beschreibungen/Notizen

• Background/aimsTo identify predictive markers for the outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD).MethodsAURA was a retrospective, observational, multicentre study that monitored the 2-year outcomes following intravitreal ranibizumab treatment in patients with nAMD. Using stepwise regression analysis, we evaluated the association between visual acuity outcomes, baseline characteristics and resource utilisation in order to determine which variables are significantly linked to outcomes in AURA. We also examined the relationship between visual acuity outcomes and number of injections received.ResultsAnalyses were performed using data from year 1 (n=1695) and year 2 completers (n=1184). Logistic analysis showed that baseline visual acuity score, age at start of therapy, number of ophthalmoscopies and optical coherence tomography (OCT) (combined) and number of injections (ranibizumab) were significant (p<0.05) prognostic factors for vision maintenance (loss <15 letters) or vision gain (≥15 letters). Patients who received >7 injections (in 1 year) or >14 injections (over 2 years) gained more letters and demonstrated greater vision maintenance (loss of <15 letters) than patients who received fewer injections. There was a significant (p<0.05) association between number of injections and national reimbursement schemes and OCT.ConclusionsA number of factors that are predictive of treatment outcomes in a real-life setting were identified. Notably, the decline of treatment benefits may be linked to number of injections and a failure to visit clinicians and receive OCT as required. These findings may be helpful in guiding ophthalmologist treatment decisions under limited time and financial constraints.Trial registration numberNCT01447043.